IQUALYSEP
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
This trial finished 3 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- mitoxantrone - immunomodulator
Compared with
- natalizumab
What it measured
Main measures
cost effectiveness
30 years
Other measures (1)
progressive neurological disability
3 years
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: * Patients with remitting multiple sclerosis according to mac Donald criteria * aggressive remitting multiple sclerosis according to following criteria: * 2 or less disabling relapse during the 12 months before inclusion * 1 or more * EDSS between 2 and 5 * aged less or equal to 40 years old for the women * effective contraception Exclusion Criteria: * patients less than 18 years old
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis
Papers
Loading reviews and guidelines…
Related trials
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Respon…
Phase 2 · Stopped early
Stopped early
- Clinical and Imaging Cohort of Neuroinflammation Diseases…
Recruiting
Still running
- AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM
Phase 1 · —
No result found
- High Dose Chemo With Stem Cell Transplant as Treatment fo…
Phase 2 · Stopped early
Stopped early
- Tolerance induction with intravenous IFNβ-1a
Phase 2 · Stopped early
Stopped early
- MITOX-REBIF
Phase 3 · Completed
No result found
History
Started
Mar 2010
Main results due
Nov 2022
Finished
Nov 2023
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error